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Background: The long-term effects of abdominal aortic aneurysm (AAA) screening were investigated in
extended follow-up from the UK Multicentre Aneurysm Screening Study (MASS) randomized trial.
Methods:A population-based sample of men aged 65–74 years were randomized individually to invitation
to ultrasound screening (invited group) or to a control group not offered screening. Patients with an
AAA (3·0 cm or larger) detected at screening underwent surveillance and were offered surgery after
predefined criteria had been met. Cause-specific mortality data were analysed using Cox regression.
Results: Some 67 770 men were enrolled in the study. Over 13 years, there were 224 AAA-related deaths
in the invited group and 381 in the control group, a 42 (95 per cent confidence interval 31 to 51) per cent
reduction. There was no evidence of effect on other causes of death, but there was an overall reduction
in all-cause mortality of 3 (1 to 5) per cent. The degree of benefit seen in earlier years of follow-up was
slightly diminished by the occurrence of AAA ruptures in those with an aorta originally screened normal.
About half of these ruptures had a baseline aortic diameter in the range 2·5–2·9 cm. It was estimated
that 216 men need to be invited to screening to save one death over the next 13 years.
Conclusion: Screening resulted in a reduction in all-cause mortality, and the benefit in AAA-related
mortality continued to accumulate throughout follow-up. Registration number: ISRCTN37381646
(http://www.controlled-trials.com).
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Introduction
National screening programmes for abdominal aortic
aneurysm (AAA) have recently been initiated for men
in England and Scotland1,2, Sweden3, and the USA
as part of Medicare4. The UK Multicentre Aneurysm
Screening Study (MASS)5–7 has provided the majority
of the worldwide randomized evidence, in terms of both
number of participants and person-years of follow-up,
for the mortality benefit following ultrasound screening
for AAA8,9. The English screening programme for men
aged 65 years is based closely on the protocol and
procedures in the MASS trial. However, there remain
some uncertainties relating to AAA screening, including
its long-term mortality benefit, and whether rescreening
of those with a previously normal scan is warranted. It
might be expected that the mortality benefit seen in
the early years after one-off screening would decrease
over time. The MASS trial, started in 1997, runs more
than 10 years ahead of the English national screening
programme, and is uniquely positioned to address these
uncertainties and inform the development of national
programmes.
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Results from MASS were last published after 10 years of
follow-up7; some increase in ruptured AAA among those
screened normal was noted, but this had not impacted
on the overall proportionate reduction in AAA-related
mortality. The only existing randomized trial evidence
after 10 years comes from much smaller trials; the 14-
year follow-up of the Danish Viborg trial did not report
on ruptured AAA among those screened normal10, whereas
the 15-year follow-up of the UK Chichester trial suggested
a possibly substantial increase in ruptured AAA during later
follow-up11. Such an increase would reduce the long-term
benefit from a single initial scan. To provide more reliable
evidence, new information is now available from the MASS
trial.
Methods
The design of the MASS trial has been described in
detail elsewhere5. In brief, a population-based sample of
men aged 65–74 years were recruited in 1997–1999 from
four centres in the UK, and randomized to receive an
invitation to screening (invited group) or not (control
group). Randomization was conducted centrally using
computer-generated pseudo-random numbers, stratified
by centre and general practice. The anterior–posterior
and transverse internal diameters of the abdominal aorta
were measured ultrasonographically, and the higher value
was recorded as the aortic diameter. Men with an aortic
diameter of 3 cm or greater were diagnosed with an
AAA. Aortas with a smaller diameter were classified as
normal (recorded simply as less than 3·0 cm) and these
men were not recalled for further imaging. Within the
group of detected AAAs, surveillance involved repeat
imaging annually for aneurysms with an aortic diameter of
3·0–4·4 cm and every 3 months for thosewith a diameter of
4·5–5·4 cm. Referral to a hospital vascular department for
consideration for elective surgery wasmadewhen the aortic
diameter reached 5·5 cm, aortic expansion was 1·0 cm or
more in 1 year, or symptoms attributable to the aneurysm
were reported.
Additional data were collected from local hospital
records relating to ultrasound scans and AAA surgery.
Deaths up to 31 March 2011 were notified by the UK
Office for National Statistics following matching on the
unique National Health Service (NHS) number for each
individual. Follow-up ranged from 11·9 to 14·2 (mean
13·1) years. The primary outcome of interest, AAA-related
mortality, was defined as all deaths within 30 days of any
AAA operation (elective or emergency) plus all deaths
with International Classification of Diseases (ICD) 9 codes
441.3–441.6. Where possible, the baseline scans were
retrieved for men screened normal who subsequently had
anAAA rupture, and the aortic diameterwas remeasured (to
give an exact result in millimetres) by a single experienced
radiologist.
Extended follow-up in MASS was approved by
Southampton and South West Hampshire Ethics Com-
mittee (A), March 2007.
Analysis
AAA-related mortality (censoring other causes of death)
and all-cause mortality were compared between the two
randomized groups using unadjusted Cox regression. An
unbiased randomization-based estimate of the benefit
of attending initial screening was also obtained12. This
estimate was calculated by subtracting from the controls
a group equivalent to the non-attending group among
those invited, leaving a control group comparable with
those attending in the invited group. The effects of age
on contraindication to, or refusal of, elective surgery and
on 30-day mortality after elective surgery were estimated
by logistic regression, taking into account calendar year
and, for 30-day mortality, group (control, invited attendee,
invited non-attendee) and type of AAA surgery (open or
endovascular aneurysm repair).
Results
Of a total of 70 495 men aged 64–75 years, 67 770
were randomized (details in Supplementary Fig. S1). The
randomized groups were well balanced in terms of age,
geographical area and socioeconomic status5,13. Among
the 33 883 men invited to screening, principally in a
primary care setting, 27 204 (80·3 per cent) attended. Of
the 1334 men (4·9 per cent prevalence) with an AAA
detected at the initial scan, 942 (70·6 per cent) had
complete clinical follow-up to 13 years according the
protocol; about half of the losses occurred during the
first 3 years of the trial. Follow-up for mortality was almost
complete (97·1 per cent); the remainder (mainly those who
had moved abroad) were censored at the time last known
to be alive. The mean age of the men in MASS at the end
of follow-up was 83 years.
Among the 1334 patients with an AAA detected at
screening, 820 had died by the end of follow-up, of whom
477 (58·2 per cent) neither had a ruptured aneurysm nor
had undergone AAA repair. Of the 514 who were still
alive at the end of follow-up, 216 (42·0 per cent) had not
undergone AAA surgery. There were about twice as many
elective AAA operations in the invited group as in the
control group (600 versus 277), but only half the emergency
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Table 1 Operations for abdominal aortic aneurysm over 13 years and subsequent 30-day mortality in the Multicentre Aneurysm
Screening Study
Control group Invited group
Operations Deaths Operations Deaths
Elective surgery 277 14 (5·1) 600 23 (3·8)
Through screening programme 0 536 17
Not through screening programme* 277 14 64 6
Emergency surgery 166 57 (34·3) 80 27 (34)
For ruptured AAA 144 54 59 23
For symptomatic AAA 22 3 21 4
Other† 2 0 14 1
Values in parentheses are percentages. *In non-attendees at initial scan or in those not undergoing regular surveillance. †Operations primarily for iliac
aneurysm, with abdominal aortic aneurysm (AAA) surgery done at the same time.
operations (80 versus 166) (Table 1). The overall 30-day
mortality rate after elective surgery was 4·2 per cent (37
of 877); it increased with age at operation (odds ratio per
5 years 1·6, 95 per cent confidence interval (c.i.) 0·9 to 2·9),
but did not differ between the invited and control groups
(P = 0·403).
Only 12·8 per cent of the elective operations were
by endovascular aneurysm repair: the 30-day mortality
rate was 1·8 per cent (2 of 112) after endovascular and
4·6 per cent (35 of 765) after open repair. The overall
turn-down rate (contraindications and refusals) for elective
surgery was 14·6 per cent (115 of 787); it increased with
age at consultation (odds ratio per 5 years 1·6, 95 per cent
c.i. 1·1 to 2·3). The 30-day mortality rate after emergency
surgery was 34·1 per cent (84 of 246), with similar rates in
each randomized group (Table 1).
There were 224 AAA-related deaths (absolute risk
0·66 per cent) in the invited group compared with 381
(1·12 per cent) in the control group, a relative risk
reduction of 42 per cent (hazard ratio 0·58, 95 per cent
c.i. 0·49 to 0·69) (Table 2). There was no evidence that the
relative risk reduction varied by baseline age or centre (tests
for interaction P = 0·586 and P = 0·531 respectively).
The number of men needed to be invited to screening
to save one death over 13 years was estimated as 216.
The AAA mortality curves in the two groups continued
to diverge throughout follow-up (Fig. 1). However, there
was a slight reduction in the benefit seen after 10 years;
from randomization to 10 years the risk reduction was
48 per cent, whereas during years 10–13 it was 20 per cent.
Over the whole 13-year interval, non-fatal AAA ruptures
were also approximately halved in the invited group
(Table 2). The numbers of non-AAA-related deaths were
similar between randomized groups (Table 2); the reduction
in ischaemic heart disease deaths in the invited group was
not statistically significant (P = 0·080). Overall, there was
Table 2 Abdominal aortic aneurysm-related mortality, rupture
and all-cause mortality over 13 years in the Multicentre
Aneurysm Screening Study
Control
group
(n = 33887)
Invited
group
(n = 33883)
Person-years of follow-up 350800 353100
AAA-related deaths
Within 30 days of 14 24
elective operation‡
From ruptured AAA§ 327 170
From AA rupture, 40 30
unspecified site¶
Total* 381 (1·09) 224 (0·63)
Hazard ratio† 1·00 (reference) 0·58 (0·49, 0·69)
Ruptured AAA
Non-fatal# 95 49
Total* ** 476 (1·36) 273 (0·77)
Hazard ratio† 1·00 (reference) 0·57 (0·49, 0·66)
Non-AAA causes of death
Ischaemic heart disease 3049 2935
Stroke 926 918
Other cardiovascular 1050 1076
Cancer 4768 4755
Other†† 3960 3950
All-cause deaths* 14 134 (40·3) 13 858 (39·2)
Hazard ratio† 1·00 (reference) 0·97 (0.95 to 0·99)
Values in parentheses are *rate per 1000 person-years and †95 per cent
confidence intervals. ‡Includes those with International Classification of
Diseases (ICD) 9 codes 441.3–441.6 who died within 30 days of elective
abdominal aortic aneurysm (AAA) surgery; §ICD-9 codes 441.3 (ruptured
AAA) and 441.4 (AAA without mention of rupture), and all deaths
occurring within 30 days of emergency AAA surgery; ¶aortic aneurysm
deaths with ICD-9 codes 441.5 (ruptured aortic aneurysm at unspecified
site) and 441.6 (aortic aneurysm at unspecified site without mention of
rupture). #Excludes nine men with non-fatal ruptured AAA in control
group and one in invited group who later died from ruptured AAA.
**AAA-related deaths plus non-fatal ruptured AAA. ††Includes 75 deaths
of unknown cause.
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Fig. 1 Abdominal aortic aneurysm (AAA)-related mortality over
13 years in the Multicentre Aneurysm Screening Study
a 3 per cent reduction in all-cause mortality in the invited
group (hazard ratio 0·97, 0·95 to 0·99).
The unbiased estimate of the 13-year reduction in AAA-
related mortality among men who attended screening was
52 per cent (hazard ratio 0·48, 0·40 to 0·59). This estimate
is relevant when providing information to individuals about
the benefit of screening, or when considering the benefit
from a screening programme that achieves an attendance
rate different from the 80 per cent achieved in MASS.
In the invited group, 24 men died within 30 days of
elective surgery and another seven after more than 30 days
(2 in-hospital deaths and 5 later AAA-related deaths). In
total, 273 men died after elective surgery or had a ruptured
AAA despite being invited for screening (Table 3). Many
of these were among those who did not attend screening
(86 men), those who did not keep a follow-up appointment
for routine surveillance or vascular assessment (27), those
who refused surgery (6) and those considered unfit for
surgery (17). Some AAA ruptures occurred between recall
scans (17), during surveillance reassessment (4), pending a
decision regarding surgery (17) and while awaiting surgery
(10).
A total of 59 ruptured AAAs occurred after a normal
first scan, of which 47 (80 per cent) were fatal. These 59
men had a mean age of 68·7 years at screening, the same
as that for all the other men who had a normal first scan.
There was a marked increase in the rate of these ruptured
aneurysms after 8 years of follow-up. By years 12–13 the
rate had increased to 8·3 per 10 000 person-years, but
remained substantially lower than the overall rate of AAA
rupture in the control group (Fig. 2). Time since initial
scan, rather than age, was the determinant of this increased
risk of rupture. It was possible to retrieve 32 of the baseline
scans for the 59 men with such a rupture (baseline scans
were not available in one centre). Among the remeasured
baseline aortic diameters, about half (18 of 32) were in the
range 2·5–2·9 cm (Fig. 3).
Table 3 Timing of abdominal aortic aneurysm ruptures and deaths in 33 883 men invited to screening
Non-fatal AAA ruptures
(n = 49)
AAA-related deaths
(n = 224)
Total
(n = 273)
AAA not identified by screening programme
Between randomization and scan 0 3 3
After non-attendance at screening (n = 6679)* 11 75 86
After non-visualized first scan (n = 329) 1 1 2
After normal first scan (n = 25541)† 12 49 61
AAA identified by screening programme
AAA < 5·5 cm‡ (n = 727)
Between recall scans 7 10 17
After non-attendance for surveillance 1 24 25
AAA ≥ 5·5 cm‡ (n = 607)
After non-attendance for vascular assessment 0 2 2
After refusal of elective surgery 0 6 6
After being declared unfit for elective surgery 0 17 17
Pending decision regarding elective surgery 9 8 17
While awaiting elective surgery 7 3 10
After return to surveillance for reassessment§ 1 3 4
After elective surgery
≤ 30 days after elective surgery 0 17 17
> 30 days after elective surgery 0 6 6
*Includes six deaths after elective operations (5 within 30 days) following incidental detection of abdominal aortic aneurysm (AAA). †Includes two deaths
within 30 days of elective surgery following incidental detection of AAA. ‡Aneurysm size based on the maximum observed from all scans. §Aneurysm of at
least 5·5 cm not confirmed at outpatient visit.
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Fig. 3 Distribution of baseline aortic diameter among 32 men
with ruptured abdominal aortic aneurysm who originally
screened normal
Discussion
The benefit of being invited to screening continued to
accumulate throughout the 13-year follow-up in the MASS
trial. The risk of AAA-related mortality and AAA rupture
was almost halved, and there was a small but convincing
reduction in all-cause mortality. The number needed to be
invited to screening to save one AAA-related death over
13 years was estimated as 216, better than, for example,
corresponding figures quoted for breast cancer screen-
ing (about 400 or more)14. Put another way, each 10 000
men screened (requiring 12 500 to be invited, assuming an
80 per cent attendance rate) saved 75 ruptured AAAs (58
fatal), leading to an extra 119 elective AAA procedures,
with an associated five postoperative deaths, over 13 years.
The overall balance of benefit to harm in terms of mortality
was in favour of screening.
The mortality benefit was somewhat less in years 10–13
after screening than before year 10. This was at least
partly due to ruptured AAA in men originally screened
normal, with a steady increase in these ruptures from year
8 onwards; the large majority of these were fatal. Although
the rate was small in absolute terms (less than 1 per 1000
per year even at years 12–13), it was enough to diminish
the benefit of AAA screening during this late follow-up.
In addition, there was a cumulative effect of incidental
AAA detection in the control group, as apparent through
the elective operations taking place, and a greater opera-
tive mortality and contraindication/refusal rate for elective
surgery as age increased. All these aspects may have con-
tributed to the reduced mortality benefit later in follow-up.
The only apparent determinants of the increased risk
of AAA rupture in those screened normal were the aortic
diameter at baseline and the time since screening. About
half of these ruptures were in men with an initial aor-
tic diameter of 2·5–2·9 cm. Based on other population
screening programmes in the UK, the proportion of
men aged 65 years with an internal aortic diameter in
the range 2·5–2·9 cm is less than 3 per cent: it reduced
from about 3 per cent to 1 per cent over 1991–2009 in
Gloucestershire15, was 2·6 per cent in Chichester and
Worthing in 2004–200716, and 1·6 per cent in the English
national screening programme in 2009–20111. In pro-
grammes measuring external aortic diameters, the propor-
tion would be expected to be somewhat higher. Although
the men in MASS had a mean age of 69 years at screening5
rather than 65 years, the increase in AAA prevalence with
age is modest13. Thus there appears to be a large difference
in the proportions of men with 2·5–2·9-cm aortic diame-
ters: among the men in MASS with an initially normal scan
whose aneurysm later ruptured it was about half, whereas
the background prevalence is less than 3 per cent.
To reduce late ruptures in future, two policies are
possible. The first would be to rescreen all men with a
normal aortic diameter, for example after 10 years, but
this would be costly. The second would be to include
those with an aortic diameter in the range 2·5–2·9 cm
in the surveillance programme. It would be sufficient to
recall these men only after, for example, 5 years in the
first instance, because the chance of developing an AAA
larger than 5·5 cm or having an AAA rupture before that
time is very small17–21. Hence the additional cost to the
surveillance programme would be modest.
Being based on a population-based sample of UK men,
the results from MASS should in principle correspond
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with the expected benefit that will derive from the NHS
AAA Screening Programme (NAAASP). However, the
prevalence of AAA (diameter at least 3·0 cm) is about
1·7 per cent in NAAASP1, compared with 4·9 per cent in
MASS, and the number of ruptured AAAs is currently
falling in the UK and elsewhere22–25. The reasons for
the lower prevalence are not fully understood, but may
partly be because NAAASP is targeting a younger age
(men aged 65 years, rather 65–74 years as in MASS), in
some NAAASP centres the ethnic mix is different, and
the uptake is lower than in MASS. In addition, there has
been a reduction in smoking prevalence and a general
reduction in cardiovascular and atherosclerotic diseases
over the intervening 15 years, together with an increased
use of some drugs (especially statins) and of elective surgery
for those aged over 75 years26,27. Therefore, although it
would still be expected that about half of the AAA-related
deaths in men aged 65 years and over in the UK should
eventually be prevented, the absolute benefit will not be as
large as in MASS.
Based on MASS data, AAA screening is a cost-effective
policy in NHS terms. The cost per life-year gained was
estimated as £7600 at 10 years7, and using health eco-
nomic modelling as £2300 over the lifetime of men aged
65 years28. These figures are both below the guideline
threshold figure of around £20 000 per life-year gained for
the acceptance of medical technologies by the National
Institute for Health and Clinical Excellence in the UK29.
Although a formal analysis of the effects of the uptake rate,
observed prevalence and aneurysm size distribution, and
current costs of the screening and operative procedures is
needed, it is expected that the NHS AAA screening pro-
gramme will still be clearly cost-effective. This is because
the main cost drivers are the elective and emergency AAA
operations30, and these (together with preoperative surveil-
lance costs for small AAAs) will be reduced roughly in
proportion to the number of AAAs detected.
Some potential limitations of the present analyses of
the MASS trial should be mentioned. The inclusion of
deaths from aortic aneurysm at an unspecified site may
have provided a conservative estimate of the benefit of
screening, because the use of ICD-9 codes 441.5 and 441.6
may have resulted in the inclusion of some non-abdominal
aortic (such as thoracic) aneurysms. Investigation of the
accuracy of cause of death coding on the death certificates
in the first 4 years of follow-up was carried out by an
independent mortality working party blinded to group
allocation, and showed that inaccuracies in coding had a
minimal impact on study outcomes5. The quality-of-life
data collected in the trial around the time of screening
showed no clear adverse (or beneficial) effects of screening,
nor any long-term effects after surgery5,31.
Although the loss to mortality follow-up was small as
patients were tracked through their NHS number, full
follow-up for surgical AAA operations was more difficult
to achieve. Surgical follow-up was through data review
of AAA operations performed at the local hospitals in
each screening area. Operations among patients who had
moved away or had surgery at other hospitals were there-
fore missed, and subsequent deaths within 30 days of the
operation would not necessarily have been recorded as
AAA-related on the death certificate. The extent of this
problem was estimated in one MASS centre, by calculat-
ing from information on death certificates the number of
deaths in hospital that occurred outside the area. This gave
a rate of 419 of 6116 (6·9 per cent); being a small propor-
tion, it indicates that only a few people in this age group
moved out of the area and were lost to surgical follow-up.
Consequently, these potentially missed data should have
had only a minor impact on the trial results.
Long-term follow-up of the MASS trial has shown that
it is possible to achieve almost a halving of the AAA-
related mortality rate by screening men aged 65–74 years.
Rescreening of all those originally screened normal is not
justified, but consideration should be given in future to
offering a further scan after about 5 years for the small
proportion of men with an aortic diameter in the range
2·5–2·9 cm.
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Commentary
Final follow-up of the Multicentre Aneurysm Screening Study (MASS)
randomized trial of abdominal aortic aneurysm screening (Br J Surg 2012; 99:
1649–1656)
The 13-year report from the Multicentre Aneurysm Screening Study (MASS) has emerged just as it is increasingly being
recognized that the benefits seen in the trial may not be reproduced by the National Health Service Abdominal Aortic
Aneurysm Screening Programme (NAAASP). Compared with MASS, the NAAASP runs in an era of a diminishing
prevalence of aneurysm rupture even without screening. Perioperative mortality rates and costs of treating aneurysms
have changed too since MASS. Still, there are lessons to be learned.
MASS invited men aged 65–74 years, whereas NAAASP is predominantly aimed at 65-year-old men. Seeking a younger
population means finding fewer aneurysms. NAAASP would find more aneurysms, at least in the short term, by actively
inviting (not just passively including) men older than 65 years. Pick-up rates at initial screening, however, are not the
whole story.
MASS reports a relative reduction in aneurysm-related death of 42 per cent, a modest return in clinical terms for
extensive effort. Targeting those with a subaneurysmal aorta at the initial scan may improve this as a substantial number
went on to aneurysm rupture later. To rescreen those with a 2·5–2·9-cm aorta appears reasonable, although data from
MASS remain incomplete in this regard.
In men initially screened normal, the risk of aneurysm rupture starts to climb after 7 years, continuing into year 13.
Some men clearly start developing an aneurysm after the initial screening. A repeat scan around 6–7 years after the initial
screen would be the most effective additional step that may improve the efficacy of the screening programme, and this
should be investigated formally.
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